19 citations
,
October 2016 in “Journal of oncology pharmacy practice” A cancer patient's hair became permanently curly after treatment with nivolumab.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology”
1 citations
,
January 2017 in “Expert opinion on orphan drugs” Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.
8 citations
,
July 2024 in “Children” Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
56 citations
,
March 2003 in “Journal of Investigative Dermatology” 17β-estradiol can reduce inflammation in the skin.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
October 2014 in “Journal of skin and stem cell” Elidel combined with tretinoin is more effective for treating alopecia areata than Elidel alone.
January 2026 in “Clinical & Translational Oncology” Early intervention and tailored management are crucial for skin side effects in cancer treatments.
April 2026 in “Frontiers in Medicine” Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
Combining excimer lamp and tofacitinib gel may help treat hair loss in children.
Early recognition and aggressive treatment can significantly improve rare ANA-negative lupus with heart and skin issues.
April 2018 in “Journal of Investigative Dermatology” Hydroxychloroquine may cause false results in tuberculosis tests for patients with autoimmune skin diseases.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
July 2025 in “Journal of Investigative Dermatology” IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.
Early recognition and a multidisciplinary approach are crucial for effectively managing complex autoimmune conditions like SLE with CAPS and AHA.
June 2024 in “British Journal of Dermatology” Dupilumab can both trigger and treat alopecia areata, often leading to hair regrowth.
116 citations
,
December 2003 in “Acta Dermato Venereologica” Iressa often causes skin issues like acne and dryness in lung cancer patients.
10 citations
,
January 2023 in “Acta dermato-venereologica” Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
4 citations
,
October 2018 in “JAMA Dermatology” Ruxolitinib may help treat hair loss and symptoms in patients with chronic graft-versus-host disease.
4 citations
,
November 2021 in “Journal of Cosmetic Dermatology” QR678 and QR678 Neo treatments, combined with corticosteroid injections, work better for alopecia areata than corticosteroid injections alone.
Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.
25 citations
,
March 2017 in “International Journal of Dermatology” Ruxolitinib effectively and safely regrows hair in alopecia patients.
15 citations
,
March 2021 in “Journal of clinical medicine” Biologic treatments for Crohn's disease and ulcerative colitis can cause skin problems, and doctors should adjust treatment if these occur.
1 citations
,
August 2025 GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
December 2025 in “Dermatology Reports” Topical ruxolitinib quickly improves non-segmental vitiligo.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Higher monocyte counts may predict poor response to adalimumab in hidradenitis suppurativa patients.